Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

Trial Profile

Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary) ; Mesenchymal stem cell therapy (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Translational Biosciences
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 26 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 26 Apr 2017 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top